Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Fitstry vs Sesame Care

Fitstry
Graded #300

Lower grade

vs+26.599999999999994
Sesame Care
Graded #2

Higher grade

The verdict

Sesame Care takes it — 87.8/100 to 61.2/100.

Sesame Care grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. An established national telehealth marketplace with the widest real brand-name GLP-1 access on the board — Wegovy (pen and pill), Zepbound, Ozempic and Mounjaro — plus provider-by-provider price transparency.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueSesame Care +55
29
84
Dose & formulationSesame Care +17
75
92
Clinical oversightSesame Care +13
81
94
Labs & monitoringSesame Care +11
73
84
FulfillmentSesame Care +13
67
80
Contract termsSesame Care +45
47
92
Fitstry · left barSesame Care · right bar

The numbers

MetricFitstrySesame Care
WeighScore61.2/10087.8/100
GradeCB+
Scorecard rank#300#2
Semaglutide$179/mo (annual plan, plus a separate fee, compounded)From $149/mo (brand Wegovy pill)
Tirzepatide$269/mo (annual plan, compounded)Brand Zepbound (price varies)
CoverageCoverage not publishedNationwide marketplace
Brand-name accessCompounded onlyYes
Oral / sublingualYesYes
Fitstry

Graded #300 · C

Strengths

  • Transparent pricing before you commit — compounded semaglutide from $179/mo, tirzepatide from $269/mo, oral GLP-1 from $209/mo (annual plan)
  • Free screening with a one-time $99 program fee that is fully refunded if a clinician can't prescribe ('Approved, or Your $99 Back')
  • Monthly price bundles a lab panel (CMP, A1c, lipids, TSH), unlimited clinician access, bi-weekly care coaching and a 24/7 Care Line
  • Runs under Weightstry, LLC, a LegitScript-certified practice with an independently verifiable seal, a named support email and phone
  • Full compounded lineup — weekly injection, daily oral tablet and microdosing options

Where it loses points

  • Month-to-month pricing is notably higher than the annual plan ($249 vs $179 semaglutide, $339 vs $269 tirzepatide)
  • Compounded semaglutide and tirzepatide only — no brand-name (Wegovy/Zepbound) options
  • Framed for women 40+, and serves 49 states rather than all 50 (the excluded state isn't disclosed publicly)
  • Works with state-licensed compounding pharmacies but doesn't name a specific pharmacy partner on the Fitstry page
  • Compounded GLP-1s are not FDA-reviewed or approved — a different evidence and regulatory tier than brand-name
Sesame Care

Graded #2 · B+

Strengths

  • Real FDA-approved brand-name access — Wegovy pen and pill, Zepbound, Ozempic, Mounjaro and Rybelsus
  • Established platform (operating since 2018) with LegitScript, BBB accreditation and large third-party review volume
  • You choose the provider and see the price up front — genuine marketplace transparency
  • Oral routes available (Wegovy pill, Rybelsus)

Where it loses points

  • A generalist marketplace, not a dedicated weight-loss program — lighter ongoing hand-holding than a specialist desk
  • Two-part cost (a platform subscription plus the medication) makes the true monthly total harder to compare
  • Brand-name cash prices can run high without insurance

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard